Enhanced AAV-mediated gene transfer for retinal therapies
Described herein are capsid proteins and adeno-associated viruses capable of targeting various types of ocular cells including bipolar and horizontal cells. Also described herein are methods of treating various ocular disorders in a subject in need thereof by administering to the subject an effective concentration of a composition comprising the recombinant adeno-associated virus (AAV) of the invention.
1. An adeno-associated virus (AAV) having a recombinant AAV capsid protein comprising SEQ ID NO: 1 or SEQ ID NO: 2.
2. An adeno-associated virus (AAV) having a recombinant AAV capsid comprising a mutation in aa 587-595 of the AAV8 capsid protein sequence as compared to the AAV8 wild type capsid sequence or a mutation in a corresponding region of another AAV capsid protein as compared to the corresponding wild type capsid sequence, further comprising a minigene comprising AAV inverted terminal repeats and a heterologous nucleic acid sequence operably linked to regulatory sequences which direct expression of a product encoded by the heterologous nucleic acid sequence in a target cell, wherein the AAV capsid comprises the sequence of SEQ ID NO: 1 or SEQ ID NO: 2.
3. The AAV according to claim 2 , wherein the product encoded by the heterologous nucleic acid sequence is an opsin selected from rhodopsin, photopsin, L/M wavelength opsin (red/green)-opsin, short wavelength (S) opsin (blue), channelrhodopsin and halorhodopsin; NYX, GRM6, TRPM1L or GPR179.
4. A composition comprising an AAV according to claim 2 and a physiologically compatible carrier.
5. The AAV according to claim 2 , wherein the AAV is a self-complementary AAV.
6. The AAV according to claim 2 , wherein the target cell is selected from a photoreceptor, RPE cell, Mueller cell, bipolar cell, ganglion cell, horizontal cell or amacrine cell.